Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis

Digestive Diseases and Sciences

Volumn 54, Issue 9, 2009, Pages 2016-2025

  Kramer, Erik Seth ^a   Hofmann, Charlotte ^b   Smith, Paula G ^b   Shiffman, Mitchell L ^b   Sterling, Richard K ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis C; Combination vaccination; HAV vaccination; HBV vaccination

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; PEGINTERFERON ALPHA2A; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; ALPHA2A INTERFERON; ANTIVIRUS AGENT; HEPATITIS B VACCINE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT RESPONSE; VACCINATION; IMMUNOLOGY; LIVER CIRRHOSIS; MIDDLE AGED; PROSPECTIVE STUDY;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; VACCINES, COMBINED;

EID: 68249141859     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0867-4     Document Type: Article

References (35)

1. ML Shiffman S Saab S Feng MI Abecassis AG Tzakis NP Goodrich DE Schaubel 2006 Liver and intestine transplantation in the United States, 1995-2004 Am J Transplant 6 1170 1187 10.1111/j.1600-6143.2006.01273.x
2. J Edeh P Spalding 2000 Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England J Public Health Med 22 531 539 10.1093/pubmed/22.4.531 (Pubitemid 32064898)
3. M Torbenson R Kannangai J Astemborski SA Strathdee D Vlahov DL Thomas 2004 High prevalence of occult hepatitis B in Baltimore injection drug users Hepatology 39 51 57 10.1002/hep.20025 (Pubitemid 38461466)
4. RC Coppola PE Manconi R Piro ML Di Martino G Masia 1994 HCV, HIV, HBV and HDV infections in intravenous drug addicts Eur J Epidemiol 10 279 283 10.1007/BF01719350 (Pubitemid 24315555)
5. AM Patti AL Santi MG Pompa C Giustini N Vescia I Mastroeni GM Fara MG Pompa 1993 Viral hepatitis and drugs: a continuing problem Int J Epidemiol 22 135 139 10.1093/ije/22.1.135
6. SA Villano KE Nelson D Vlahov RH Purcell AJ Saah DL Thomas 1997 Hepatitis A among homosexual men and injection drug users: more evidence for vaccination Clin Infect Dis 25 726 728 10.1086/513757
7. JP Zarski B Bohn A Bastie JM Pawlotsky M Baud F Bost-Bezeaux J Tran van Nhieu JM Seigneurin C Buffet D Dhumeaux 1998 Characteristics of patients with dual infection by hepatitis B and C viruses J Hepatol 28 27 33 10.1016/S0168-8278(98)80198-0 (Pubitemid 28122496)
8. E Giannini P Ceppa F Botta A Fasoli P Romagnoli F Ansaldi P Durando D Risso PB Lantieri GC Icardi R Testa 2003 Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients Liver Int 23 12 18 10.1034/j.1600-0676.2003.01742.x
9. A Alberti P Pontisso L Chemello G Fattovich L Benvegnù F Belussi MS De Mitri 1995 The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease J Hepatol 22 Suppl(1): 38 41
10. Vaccine Information Statement. Centers for disease control and prevention. < http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-hep-a.pdf >; 2006 Accessed 1.02.08.
11. World Health Organization. Public health control of hepatitis A: WHO position paper. Report No.: 75; 2000.
12. IJ Tsai MH Chang HL Chen YH Ni PI Lee TY Chiu A Safary 2000 Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults Vaccine 19 437 441 10.1016/S0264-410X(00)00205-X (Pubitemid 30750727)
13. EB Keeffe 2005 Acute hepatitis A and B in patients with chronic liver disease: prevention through vaccination Am J Med 118 Suppl 10A 21 27 10.1016/j.amjmed.2005.07.013 (Pubitemid 41552428)
14. DH Van Thiel JS Gavaler 1992 Response to HBV vaccination in patients with severe liver disease, absence of an HLA effect Dig Dis Sci 37 1447 1451 10.1007/BF01296017
15. WM Lee JL Dienstag KL Lindsay AS Lok HL Bonkovsky ML Shiffman GT Everson AM Di Bisceglie TR Morgan MG Ghany C Morishima EC Wright JE Everhart HALT-C Trial Group 2004 Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 472 492 10.1016/j.cct.2004.08.003 (Pubitemid 39299157)
16. K Ishak A Baptista L Bianchi F Callea J De Groote F Gudat H Denk V Desmet G Korb RN [tmp] MacSween 1995 Histological grading and staging of chronic hepatitis J Hepatol 22 696 699 10.1016/0168-8278(95)80226-6
17. EB Keeffe S Iwarson BJ [tmp] McMahon KL Lindsay RS Koff M Manns R Baumgarten M Wiese M Fourneau A Safary R Clemens DS Krause 1998 Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease Hepatology 27 881 886 10.1002/hep.510270336 (Pubitemid 28103570)
18. SD Lee CY Chan MI Yu YJ Wang FY Chang KJ Lo A Safary 1997 Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease J Med Virol 52 215 218 10.1002/(SICI)1096-9071(199706)52:2<215::AID- JMV16>3.0.CO;2-J (Pubitemid 27239323)
19. SW Tsang JJ Sung 1999 Inactivated hepatitis A vaccine in chinese patients with chronic hepatitis B infection Aliment Pharmacol Ther 13 1445 1449 10.1046/j.1365-2036.1999.00628.x (Pubitemid 29516256)
20. JA Dumot DS Barnes Z Younossi SM Gordon RK Avery RE Domen JM Henderson WD Carey 1999 Immunogenicity of hepatitis A vaccine in decompensated liver disease Gastroenterology 94 6 1601 1604
21. AJ Roome SJ Walsh ML Cartter JL Hadler 1993 Hepatitis B vaccine responsiveness in Connecticut public safety personnel JAMA 270 2931 2934 10.1001/jama.270.24.2931 (Pubitemid 24000798)
22. DN Fisman D Agrawal K Leder 2002 The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis Clin Infect Dis 35 1368 1375 10.1086/344271 (Pubitemid 35448965)
23. HL Bock J Kruppenbacher R Sänger W Höbel R Clemens W Jilg 1996 Immunogenicity of a recombinant hepatitis B vaccine in adults Arch Intern Med 156 2226 2231 10.1001/archinte.156.19.2226 (Pubitemid 26361916)
24. F Averhoff F Mahoney P Coleman G Schatz E Hurwitz H Margolis 1998 Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection Am J Prev Med 15 1 8 10.1016/S0749-3797(98) 00003-8 (Pubitemid 28289941)
25. M Van der Wielen P Van Damme R Chlibek J Smetana F von Sonnenburg 2006 Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors Vaccine 24 5509 5515 10.1016/j.vaccine.2006.04.016 (Pubitemid 43831382)
26. K Cardell B Akerlind M Sallberg A Fryden 2008 Excellent response to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine J Infect Dis 198 299 304 10.1086/589722
27. PD Reuman P Kubilis W Hurni L Brown D Nalin 1997 The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults Vaccine 15 1157 1161 10.1016/S0264-410X(96)00310-6 (Pubitemid 27357202)
28. N Eibl M Spatz GF Fischer WR Mayr A Samstag HM Wolf G Schernthaner MM Eibl 2002 Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study Clin Immunol 103 3 Pt 1 249 259 10.1006/clim.2002.5220 (Pubitemid 34666748)
29. S Petta C Camma V Di Marco N Alessi D Cabibi R Caldarella A Licata F Massenti G Tarantino G Marchesini A Craxi 2008 Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection Am J Gastroenterol 103 1136 1144 10.1111/j.1572-0241.2008.01813.x (Pubitemid 351677995)
30. CO Zein C Levy A Basu NN Zein 2005 Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study Am J Gastroenterol 100 48 55 10.1111/j.1572-0241.2005.40429.x (Pubitemid 41623268)
31. G DaRoza A Loewen O Djurdjev J Love C Kempston S Burnett M Kiaii PA Taylor A Levin 2003 Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better Am J Kidney Dis 42 1184 1192 10.1053/j.ajkd.2003.08.019 (Pubitemid 37486762)
32. KM Chow MC Law CB Leung CC Szeto PK Li 2006 Antibody response to hepatitis B vaccine in end-stage renal disease patients Nephron Clin Pract 103 c89 c93 10.1159/000092016 (Pubitemid 43952607)
33. J Caetano A Martinho A Paiva B Pais C Valente C Luxo 2008 Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to anti-viral therapy in patients chronically infected with HCV J Virol 82 7567 7577 10.1128/JVI.02175-07 (Pubitemid 352031224)
34. IS Elefsiniotis E Vezali K Kamposioras K Pantazis R Tonorova I Ketikoglou A Moulakakis G Saroglou 2006 Immunogenicity of recombinant hepatitis B vaccine in treatment-naïve and treatment experienced chronic hepatitis c patients: the effect of pegylated interferon plus ribavirin treatment World J Gastroenterol 12 4420 4424
35. F Siddiqui M Mutchnick J Kinzie R Peleman P Naylor M Ehrinpreis 2001 Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy Am J Gastroenterol 96 858 863 10.1111/j.1572-0241.2001.03633.x